Log In
BCIQ
Print this Print this
 

KAHR-102

  Manage Alerts
Collapse Summary General Information
Company Kahr Medical Ltd.
DescriptionFusion protein that links portions of CTLA-4 and FasL immune-related membrane proteins
Molecular Target Fas ligand (TNF superfamily, member 6) (FASL) ; Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationLymphoma
Indication DetailsTreat lmphoma
Regulatory Designation
PartnerCobra Biologics AB

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3.0M

$3.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/17/2011

$3.0M

$3.0M

0

Get a free BioCentury trial today